Cite

HARVARD Citation

    Hollifield, A. et al. (2020). Caplacizumab: an anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. American journal of health-system pharmacy. pp. 1201-1207. [Online]. 
  
Back to record